Myasthenia Gravis: Disease, Diagnosis and Management

Bhupendra G. Prajapati · Devesh U. Kapoor · Jaimin R Shah

2025年12月 · Academic Press

电子书

350

页

符合条件

该图书的上架销售日期为 2025年12月1日。图书上架后，我们才会向您收取相关费用。

关于此电子书

"Myasthenia Gravis: Disease, Diagnosis and Management" is a comprehensive resource that explores recent advancements in diagnosing and treating Myasthenia Gravis, a rare autoimmune disease affecting the neuromuscular junction. With contributions from global experts, this book addresses the increasing prevalence of Myasthenia Gravis, reflecting the latest in diagnostic techniques and novel therapies such as complement inhibitors and FcRn antagonists. It aims to support healthcare professionals in delivering optimal care through evidence-based insights and patient-centered approaches. The book is divided into several chapters, beginning with an overview of the pathogenesis and immunoregulatory defects in Myasthenia Gravis. Subsequent chapters cover diagnostic methods, non-immunosuppressive treatments, and biological therapies targeting the immune system. Key topics include the role of intravenous immunoglobulin (IVIg) and plasma exchange (PLEX) in severe exacerbations, thymectomy, molecular mechanisms, and the potential of hematopoietic stem cell transplants. The book also delves into precision medicine, AI applications, clinical trial considerations, and novel therapeutics like anti-FcRn antibodies. Management strategies for ocular Myasthenia Gravis, and a holistic view of living with the disease are also discussed. "Myasthenia Gravis: Disease, Diagnosis and Management" is invaluable for healthcare providers, physicians, immunologists, ophthalmologists, rheumatologists, physical therapists, pharmacists, and translators. It offers a modern guide to understanding and managing Myasthenia Gravis, integrating clinical expertise with the latest research to improve patient outcomes.• Explores pathogenesis, diagnosis, and treatment options for Myasthenia Gravis, providing a complete understanding of the disease• Highlights cutting-edge therapies like complement inhibitors and FcRn antagonists for improved patient outcomes• Ensures authoritative and up-to-date information contributed by global experts• Offers evidence-based strategies for healthcare professionals to optimize Myasthenia Gravis management• Integrates clinical expertise with patient-centered care for a well-rounded perspective on disease management

作者简介

Dr. Bhupendra G. Prajapati is Professor in the Department of Pharmaceutics at School of Pharmacy, P P Savani University, Kosamba-394125, Gujarat 394125, India. An alumnus of Hemchandracharya North Gujarat University (Doctorate) and M.S. University of Baroda (B.Pharm and M.Pharm), he has over 22 years of experience in academia, research, and industry. Dr. Prajapati has received numerous accolades, including the AICTE's Career Award for Young Teacher and the President Award for Staff Excellence in Research and Capacity Building from Ganpat University. With over 80 national and international publications, he has secured various research grants and holds multiple patents in NDDS. He has supervised numerous Ph.D. and PG research scholars and delivered over 50 expert talks globally. As an editor of 10 international books and contributor of 70 book chapters, his research focuses on lipid-based drug delivery and nanotech formulations. Dr. Prajapati is an active member of IPA, APTI, and CRSIC..

Dr. Devesh U. Kapoor is a Professor at Dr. Dayaram Patel Pharmacy College, Bardoli, Gujarat, where he has served since September 2010. He holds a B.Pharm from the University of Rajasthan and an M.Pharm in Pharmaceutics from Rajasthan University of Health Sciences, along with a PhD in pharmaceutical sciences. With 14 years of teaching and administrative experience, Dr. Kapoor has authored over 35 research and review articles in esteemed national and international journals and contributed to several books published by Elsevier, Bentham Science, MDPI, Springer, and Wiley. His research focuses on osmotic drug delivery systems, solid lipid nanoparticles, and microspheres. He has received significant grants for organizing national seminars and faculty development programs. Dr. Kapoor holds three design patents and has delivered over 10 expert talks at various national conferences. He is currently the editor of three international books with prominent publishers.

Jaimin R. Shah is the Founder, President, and CEO of Upsilon Innovations and a researcher at the University of California San Diego. With over 14 years of experience in academia and industry, he has been a key member of multiple pharmaceutical startups and has worked on over 80 product development projects. Dr. Shah specializes in innovative drug delivery technologies, focusing on cancer, autoimmune diseases, rare diseases, and regenerative medicine. He has published numerous research papers, co-authored book chapters, and holds multiple patents. His expertise spans various dosage forms, including transdermal, topical, lipid-based systems, ophthalmics, and injectables. Dr. Shah holds a B.Pharm from Gujarat University, an M.S. in Pharmaceutics from Long Island University, and a Ph.D. in Materials Science and Engineering from UC San Diego. He is an active member of AAPS, ACS, AACR, and RSC.